Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mural Oncology Plc (MURA)
:MURA
MURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.87 - $5.62
Previous CloseN/A
Volume157.34K
Average Volume (3M)194.51K
Market Cap
$73.53M
Enterprise Value-$112.66M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Apr 01, 2025EPS Estimate
-1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.14
Shares Outstanding17,060,310
10 Day Avg. Volume168,159
30 Day Avg. Volume194,507
Standard Deviation0.23
R-Squared0.24
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit43.89
Enterprise Value/Ebitda0.73
Forecast
1Y Price Target
$14.50Price Target Upside239.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Mural Oncology Plc News
PremiumCompany Announcements
Mural Oncology Advances Drug Pipeline and Extends Runway
PremiumStock Analysis & Ideas
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressInterim survival data from the Phase 3 trial in ovarian cancer could lead to potential approval, significantly impacting investors' perception of MURA.
Financial PerformanceStock is currently trading at a deep discount to cash, with a potential for the stock price to increase significantly based on future positive data.
Product DifferentiationMural’s nemvaleukin is engineered to selectively target the IL-2 receptor βγ complex, avoiding the toxicity issues that have limited the use of traditional IL-2 therapies.
Bears Say
Clinical Trial RiskInterim analysis failing to show any improvement in survival over the control arm could result in the study being terminated.
Investor SentimentStock is currently trading at a negative EV, >60% discount to cash, with potential for significant price increase based on positive data.
Market PerceptionInvestors have been highly skeptical of IL-2 programs due to past failures by other companies, creating an overhang on the IL-2 drug space.
---
Ownership Overview
2.51% Insiders
7.21% Mutual Funds
37.17% Other Institutional Investors
48.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MURA FAQ
What was Mural Oncology Plc’s price range in the past 12 months?
Mural Oncology Plc lowest stock price was $2.87 and its highest was $5.62 in the past 12 months.
What is Mural Oncology Plc’s market cap?
Mural Oncology Plc’s market cap is $73.53M.
When is Mural Oncology Plc’s upcoming earnings report date?
Mural Oncology Plc’s upcoming earnings report date is Apr 01, 2025 which is in 39 days.
How were Mural Oncology Plc’s earnings last quarter?
Mural Oncology Plc released its earnings results on Nov 13, 2024. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$1.972 by $0.102.
Is Mural Oncology Plc overvalued?
According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued.
Does Mural Oncology Plc pay dividends?
Mural Oncology Plc does not currently pay dividends.
What is Mural Oncology Plc’s EPS estimate?
Mural Oncology Plc’s EPS estimate is -1.99.
How many shares outstanding does Mural Oncology Plc have?
Mural Oncology Plc has 17,060,310 shares outstanding.
What happened to Mural Oncology Plc’s price movement after its last earnings report?
Mural Oncology Plc reported an EPS of -$1.87 in its last earnings report, beating expectations of -$1.972. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mural Oncology Plc?
Currently, no hedge funds are holding shares in MURA
---
Mural Oncology Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.50 (239.58% Upside)
$14.50 (239.58% Upside)
Blogger Sentiment
Bullish
MURA Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.38%
12-Months-Change
Fundamentals
Return on Equity
-183.89%
Trailing 12-Months
Asset Growth
573.05%
Trailing 12-Months
Company Description
Mural Oncology Plc
Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab.
---
MURA Stock 12 Month Forecast
Average Price Target
$14.50
▲(239.58% Upside)
Technical Analysis
Best Analysts Covering MURA
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+26.64%
reiterated a buy rating last month
Copying Judah Frommer's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +26.64% per trade.
---